A Review of New Atypical Antipsychotic Launches in the United States

| December 27, 2010 | 0 Comments

by Jeff Ventimiglia, BSE; Amir H. Kalali, MD; and Leslie Citrome, MD, MPH

Mr. Ventimiglia is a Senior Analyst in Clinical Development Services, Quintiles, Inc., Durham, North Carolina; Dr. Kalali is Vice President, Global Therapeutic Group Leader CNS, Quintiles, Inc., and Professor of Psychiatry, University of California, San Diego in San Diego, California; Dr. Citrome is Professor of Psychiatry, New York University School of Medicine, New York

Psychiatry (Edgemont) 2010;7(12):13–15

The content you are trying to view is restricted to registered members only.
Membership to Innovations in Clinical Neuroscience is free, so please consider becoming a member today.
Thank you
ICNS Online Editor
Please Login or Register for access.

Tags: , , , , , , , , , , , , ,

Category: Bipolar Disorder, Past Articles, Psychiatry, Psychopharmacology, Schizophrenia, Trend Watch

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.